LaTrice Montgomery1, Kara Bagot2, Jennifer L Brown3, Angela M Haeny4. 1. Addiction Sciences Division, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Suite 104, Cincinnati, OH, 45229, USA. latrice.montgomery@uc.edu. 2. Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, MC 0405, La Jolla, CA, 92093, USA. 3. Addiction Sciences Division, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, 3131 Harvey Avenue, Suite 104, Cincinnati, OH, 45229, USA. 4. Division of Prevention and Community Research, Yale School of Medicine, The Consultation Center, 389 Whitney Avenue, New Haven, CT, 06511, USA.
Abstract
PURPOSE OF REVIEW: Approximately 77% of HIV-infected adults report lifetime marijuana use. Given the high rates and social acceptability of marijuana use among HIV-infected individuals, it is important to gain a stronger understanding of if, and how, marijuana impacts HIV care cascade outcomes. The purpose of this study is to systematically review recent articles that assess the relationship between marijuana use and HIV continuum of care outcomes. RECENT FINDINGS: One hundred and ninety articles from PubMed were considered for inclusion, and 15 were included in the review. The studies focus on marijuana use among HIV-infected individuals aware of their serostatus (k = 4), individuals engaged in treatment (k = 1), marijuana use in association with adherence to antiretroviral medications (k = 6), and marijuana use in relation to multiple stages of the HIV care cascade (k = 4). Preliminary findings from the small number of studies revealed an association between marijuana use, especially current heavy use, and HIV seropositivity. However, results from studies assessing marijuana use and treatment engagement and adherence to antiretroviral medications were inconsistent and inconclusive. Additional research is needed to assess the nuanced relationship between marijuana use and HIV continuum of care outcomes, especially among subgroups of HIV-infected individuals, such as men who have sex with men and young adults.
PURPOSE OF REVIEW: Approximately 77% of HIV-infected adults report lifetime marijuana use. Given the high rates and social acceptability of marijuana use among HIV-infected individuals, it is important to gain a stronger understanding of if, and how, marijuana impacts HIV care cascade outcomes. The purpose of this study is to systematically review recent articles that assess the relationship between marijuana use and HIV continuum of care outcomes. RECENT FINDINGS: One hundred and ninety articles from PubMed were considered for inclusion, and 15 were included in the review. The studies focus on marijuana use among HIV-infected individuals aware of their serostatus (k = 4), individuals engaged in treatment (k = 1), marijuana use in association with adherence to antiretroviral medications (k = 6), and marijuana use in relation to multiple stages of the HIV care cascade (k = 4). Preliminary findings from the small number of studies revealed an association between marijuana use, especially current heavy use, and HIV seropositivity. However, results from studies assessing marijuana use and treatment engagement and adherence to antiretroviral medications were inconsistent and inconclusive. Additional research is needed to assess the nuanced relationship between marijuana use and HIV continuum of care outcomes, especially among subgroups of HIV-infected individuals, such as men who have sex with men and young adults.
Authors: Donald I Abrams; Joan F Hilton; Roslyn J Leiser; Starley B Shade; Tarek A Elbeik; Francesca T Aweeka; Neal L Benowitz; Barry M Bredt; Bradley Kosel; Judith A Aberg; Steven G Deeks; Thomas F Mitchell; Kathleen Mulligan; Peter Bacchetti; Joseph M McCune; Morris Schambelan Journal: Ann Intern Med Date: 2003-08-19 Impact factor: 25.391
Authors: Inge B Corless; Teri Lindgren; William Holzemer; Linda Robinson; Shahnaz Moezzi; Kenn Kirksey; Christopher Coleman; Yun-Fang Tsai; Lucille Sanzero Eller; Mary Jane Hamilton; Elizabeth F Sefcik; Gladys E Canaval; Marta Rivero Mendez; Jeanne K Kemppainen; Eli H Bunch; Patrice K Nicholas; Kathleen M Nokes; Pamela Dole; Nancy Reynolds Journal: Clin Nurs Res Date: 2009-05 Impact factor: 2.075
Authors: Lisa M Kuhns; Anna L Hotton; Rob Garofalo; Abigail L Muldoon; Kaitlyn Jaffe; Alida Bouris; Dexter Voisin; John Schneider Journal: AIDS Patient Care STDS Date: 2016-04 Impact factor: 5.078
Authors: Margaret Haney; Erik W Gunderson; Judith Rabkin; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Lauren Lipira; Deepa Rao; Paul E Nevin; Christopher G Kemp; Susan E Cohn; Janet M Turan; Jane M Simoni; Michele P Andrasik; Audrey L French; Joseph M Unger; Patrick Heagerty; Emily C Williams Journal: Drug Alcohol Depend Date: 2019-11-20 Impact factor: 4.492
Authors: Tiffany R Glynn; Noelle A Mendez; Deborah L Jones; Sannisha K Dale; Adam W Carrico; Daniel J Feaster; Allan E Rodriguez; Steven A Safren Journal: J Behav Med Date: 2020-10-24
Authors: S A Meyers-Pantele; H J Rendina; A J Talan; O Shalhav; S Lammert; K J Horvath Journal: Drug Alcohol Depend Date: 2021-07-28 Impact factor: 4.852
Authors: Michael L Dennis; Corey N Smith; Steven Belenko; Danica Knight; Larkin McReynolds; Grace Rowan; Richard Dembo; Ralph DiClemente; Angela Robertson; Tisha Wiley Journal: Fed Probat Date: 2019-09
Authors: Jordan N Kohn; Matthew Shane Loop; Julie J Kim-Chang; Patricia A Garvie; John W Sleasman; Bernard Fischer; H Jonathon Rendina; Steven Paul Woods; Sharon L Nichols; Suzi Hong Journal: J Acquir Immune Defic Syndr Date: 2021-06-01 Impact factor: 3.771
Authors: Jessica S Flannery; Michael C Riedel; Taylor Salo; Ranjita Poudel; Angela R Laird; Raul Gonzalez; Matthew T Sutherland Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2021-07-03 Impact factor: 5.067